The statin-iron nexus: Anti-inflammatory intervention for arterial disease prevention

American Journal of Public Health

Volumn 103, Issue 4, 2013, Pages

  Zacharski, Leo R ^a,b   DePalma, Ralph G ^c,d   Shamayeva, Galina ^a   Chow, Bruce K ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LOW DENSITY LIPOPROTEIN;

AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD; CHI SQUARE DISTRIBUTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GOVERNMENT; HUMAN; INFLAMMATION; IRON OVERLOAD; MALE; METABOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; UNITED STATES;

AGED; ATHEROSCLEROSIS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; IRON; IRON OVERLOAD; LINEAR MODELS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

MLCS; MLOWN;

EID: 84875129346     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2012.301163     Document Type: Article

References (150)

1. Last AR, Ference JD, Falleroni J. Pharmacologic treatment of hyperlipidemia. Am Fam Physician. 2011;84(5):551-558.
2. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. NEnglJMed. 1998;339(19): 1349-1357.
3. US Food and Drug Administration. FDA Approves Rosuvastatin for Cardiovascular Disease Prevention. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm200128.htm. Accessed November 20, 2012.
4. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-2207.
5. Galper BZ, Moran A, Coxson PG, et al. Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis. Circulation. 2012;125(2):260-270.
6. Stuart C. Circ: Universal Statin Therapy Is Cost Effective for Mid-Risk CHD. Available at: http://www.healthimagingcom/index.php?option=com- articles&article=30799. Accessed November 20, 2012.
7. Stuart C. Circ: Universal Statin Therapy Is Cost Effective for Mid-Risk CHD. Available at: http://www.cardiovascularbusiness.com/index.php?option=com- articles&view=article&id=30799:circ-universal-statin-therapy-is-cost- effective-for-mid-risk-chd. Accessed November 20, 2012.
8. American Academy of Pediatrics. New AAP Policy on Lipid Screening and Heart Health in Children. Available at: http://www.aap.org/advocacy/releases/ july08lipidscreening.htm. Accessed November 20, 2012.
9. Psaty BM, Rivara FP. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA. 2012;307(3):257-258.
10. Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA. 2012;307(3):259-260.
11. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995;29 (7-8):743-759.
12. El-Salem K, Ababneh B, Rudnicki S, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011;44(6):877-881.
13. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172(2):144-152.
14. Mascitelli L, Pezzetta F, Goldstein MR. The epidemic of nonmelanoma skin cancer and the widespread use of statins: is there a connection? Dermatoendocrinol. 2010;2(1):37-38.
15. Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C. Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin. J R Coll Physicians Edinb. 2010;40(1):33-36.
16. Tirkkonen T, Ryynänen A, Vahlberg T, et al. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study. Drug Saf 2008;31(3):231-240.
17. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med. 2001;94(9): 339-341.
18. Heron MP, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57(14):1-52.
19. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes. 2012;5(1):2-5.
20. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160-1164.
21. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol. 1999;10 (6):543-559.
22. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholes-terolemic animals. Nat Med. 2000;6(9):1004-1010
23. Erratum in: Nat Med. 2001;7(1):129.
24. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286(5446):1946-1949.
25. Sobal G, Sinzinger H. Effect of simvastatin on the oxidation of native and modified lipoproteins. Biochem Pharmacol. 2005;70(8):1185-1191.
26. Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011;22(3):165-170.
27. Yilmaz MI, Baykal Y, Kilic M, et al. Effects of statins on oxidative stress. Biol Trace Elem Res. 2004;98(2): 119-127.
28. Lian WS, Lin H, Cheng WT, Kikuchi T, Cheng CF. Granulocyte-CSF induced inflammation-associated cardiac thrombosis in iron loading mouse heart and can be attenuated by statin therapy. J Biomed Sci. 2011;18:26.
29. Sezer ED, Sozmen EY, Nart D, Onat T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag. 2011;7:333-343.
30. Ridker PM, Cannon CP, Morrow D, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22. (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352 (1):20-28.
31. Levenson CW, Tassabehji NM. Iron and ageing: an introduction to iron regulatory mechanisms. Ageing Res Rev. 2004;3(3):251-263.
32. Gey KF. Prospects for the prevention of free radical disease, regarding cancer and cardiovascular disease. Br Med Bull. 1993;49(3):679-699.
33. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the etiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics. 2009;2:2.
34. Yuan XM, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann Med. 2003;35(8): 578-591.
35. You SA, Wang Q. Ferritin in atherosclerosis. Clin Chim Acta. 2005;357(1):1-16.
36. Spiteller G. Is atherosclerosis a multifactorial disease or is it induced by a sequence of lipid peroxidation reactions? AnnN Y Acad Sci. 2005;1043:355-366.
37. Mascitelli L, Goldstein MR. Might the beneficial effects of statin drugs be related to their action on iron metabolism? QJM. 2012;105(12):1225-1229.
38. DePalma RG, Hayes VW, Cafferata HT, et al. Cytokine signatures in atherosclerotic claudicants. J Surg Res. 2003;111(2):215-221.
39. Depalma RG, Hayes VW, Chow BK, et al. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) trial. J Vasc Surg. 2010;51(6):1498- 1503.
40. DePalma RG, Hayes VW, May PE, et al. Statins and biomarkers in claudicants with peripheral vascular disease. Vascular. 2006;14(4):193-200.
41. Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIOJ. 2003;49(4):422-425.
42. Ukinc K, Ersoz HO, Erem C, Hacihasanoglu AB, Karti SS. Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine. 2009;35(3):380-388.
43. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J. 2011;162(5):949-957.
44. Zacharski LR, Chow BK, Howes PS, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease. JAMA. 2007;297(6): 603-610.
45. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J. 2000;140(1):98-104.
46. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
47. Cox DR. Regression models and life-tables. J R Stat Soc, B. 1972;34:187-220.
48. Ali F, Hamdulay SS, Kinderlerer AR, et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost. 2007;5 (12):2537-2546.
49. Leung PO, Wang SH, Lu SH, et al. Simvastatin inhibits pro-inflammatory mediators through induction of heme oxygenase-1 expression in lipopolysaccharide-stimulated RAW2 64.7 macrophages. Toxicol Lett. 2011;207(2):159-166.
50. Kwok SC, Samuel SP, Handal J. Atorvastatin activates heme oxygenase-1 at the stress response elements. J Cell Mol Med 2012;16(2):394-400.
51. Hinkelmann U, Grosser N, Erdmann K, Schröder H, Immenschuh S. Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci. 2010;41(1):118-124.
52. Gueler F, Park JK, Rong S, et al. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol. 2007;170(4):1192-1199.
53. Tu YP, Chuang SJ, Chen SC, Liu YH, Chen CF, Hour TC. Simvastatin induces the expression of hemeoxygenase-1 against ischemia-reperfusion injury on the testes in rats. Toxicol Lett 2011;207(3):242-250.
54. Chen JC, Huang KC, Lin WW.HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal. 2006;18(1): 32-39.
55. Immenschuh S, Schröder H. Heme oxygenase-1 and cardiovascular disease. Histol Histopathol. 2006;21(6): 679-685.
56. Cheng C, Noordeloos AM, Jeney V, et al. Heme oxygenase 1 determines atherosclerotic lesion progression into a vulnerable plaque. Circulation. 2009;119(23): 3017-3027.
57. Heeba G, Moselhy ME, Hassan M, et al. Antiatherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1. Br J Pharmacol. 2009;156(8):1256-1266.
58. Sullivan JL. Regarding "Statins, heme oxygenase-1, iron, and atherosclerosis.". J Vasc Surg. 2010;52(2):536-537.
59. Sullivan JL. Do hemochromatosis mutations protect against iron-mediated atherogenesis? Circ Cardiovasc Genet. 2009;2(6):652-657.
60. Han J, Zhou X, Yokoyama T, et al. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation. 2004;109(6): 790-796.
61. Kraml PJ, Klein RL, Huang Y, Nareika A, Lopes-Virella MF. Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. Metabolism. 2005; 54(4):453-459.
62. Li W, Hellsten A, Xu LH, et al. Foam cell death induced by 7 beta-hydroxycholesterol is mediated by labile iron-driven oxidative injury: mechanisms underlying induction of ferritin in human atheroma. Free Radic Biol Med 2005;39(7):864-875.
63. Daugherty A, Rateri DL, Lu H. As macrophages indulge, atherosclerotic lesions bulge. Circ Res. 2008;102(12):1445-1447.
64. Valenti L, Dongiovanni P, Motta BM, et al. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011;31(3):683-690.
65. Saeed O, Otsuka F, Polavarapu R, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32(2):299-307.
66. Li JJ, Meng X, Si HP, et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol. 2012;32(5):1158-1166.
67. Arabul M, Gullulu M, Yilmaz Y, et al. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clin Biochem. 2008;41(13): 1055-1058.
68. Ganz T, Nemeth E. Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta. 2006;1763(7):690-699.
69. Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol. 2008;51(17):1653-1662.
70. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003; 108(4):426-431.
71. Day SM, Duquaine D, Mundada LV, et al. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003;107(20):2601-2606.
72. van Asperen IA, Feskens EJ, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol. 1995;24 (4):665-670.
73. Yuan XM, Li W. Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr Med Chem. 2008;15(21):2157-2172.
74. Li W, Ostblom M, Xu LH, et al. Cytocidal effects of atheromatous plaque components: the death zone revisited. FASEBJ. 2006;20(13):2281-2290.
75. Baynes R, Bezwoda W, Bothwell T, Khan Q, Mansoor N. The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein. Scand J Clin Lab Invest. 1986;46(7):695-704.
76. Coffman LG, Parsonage D, D'Agostino R Jr, Torti FM, Torti SV. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci USA. 2009;106(2):570-575.
77. Zheng H, Cable R, Spencer B, Votto N, Katz SD. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol 2005;25(8):1577-1583.
78. Yang Q, Jian J, Abramson SB, Huang X. Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res. 2011;26(6):1188-1196.
79. Salonen JT, Korpela H, Nyyssonen K, et al. Lowering of body iron stores by bloodletting and oxidation resistance of serum lipoproteins: a randomized crossover trial in male smokers. J Intern Med. 1995;237(2):161-168.
80. Schroeter MR, Humboldt T, Schäfer K, Konstantinides S. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilization and recruitment in apolipoprotein E knockout mice. Atherosclerosis. 2009;205(1):63-73.
81. Rosenthal EA, Bohlmeyer TJ, Monnet E, et al. An iron-binding exochelin prevents restenosis due to coronary artery balloon injury in a porcine model. Circulation. 2001;104(18):2222-2227.
82. Ghosh S. Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization. Expert Rev Cardiovasc Ther. 2011;9 (3):329-340.
83. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364 (2):127-135.
84. Feig JE, Shang Y, Rotllan N, et al. Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS ONE. 2011;6(12):e28534.
85. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1. Horm Metab Res. 2011;43(9):619-624.
86. Song G, Liu J, Zhao Z, et al. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet. Lipids Health Dis. 2011;10:8.
87. Kralova-Lesna I, Adámkova V, Pagacova L. Effect of rosuvastatin treatment on cholesterol efflux from human macrophages. Neuroendocrinol Lett. 2011;32(suppl 2):24-28.
88. Siwek J, Gourlay ML, Slawson DC, Shaughnessy AF. How to write an evidence-based clinical review article. Am Fam Physician. 2002;65(2):251-258.
89. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011;31(11):1409-1417.
90. Buijsse B, Feskens EJ, Moschandreas J, et al. Oxidative stress, and iron and antioxidant status in elderly men: differences between the Mediterranean south (Crete) and northern Europe (Zutphen). Eur J Cardiovasc Prev Rehabil. 2007;14(4):495-500.
91. Health-e-Iron. Ferrotoxic Disease: Quantitative Effects of Iron Excess on Health. Available at: www.healtheiron.com. Accessed November 20, 2012.
92. Riccioni G, Vitulano N, Mancini B, Zanasi A, D'Orazio N. One year treatment with rosuvastatin reduces intima media thickness in 45 hypercholesterolemic subjects with asymptomatic carotid artery disease. Pharmacology. 2010;85(2):63-67.
93. Kadoglou NP, Gerasimisdis T, Moumtzouglou A, et al Intensive lipid lowering ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg. 2008;35(6):661-668.
94. Coppola G, Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch Med Res. 2007;38(5):479-488.
95. Ahluwalia N, Genoux A, Ferrieres J, et al. Iron status is associated with carotid plaques in middle aged adults. J Nutr. 2010;140(4):812-816.
96. Kiechl S, Willeit J, Egger MD, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997;96(10):3300-3307.
97. Ellervik C, Tybjaerg-Hansen A, Appleyard M, et al. Hereditary hemochromatosis genotypes and risk of ischemic stroke. Neurology. 2007;68(13):1025-1031.
98. Fernández-Real JM, Peñarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes. 2002;51(4):1000-1004.
99. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyper-ferritinemia: evidence from a case-control study. Am J Gastroenterol. 2007; 102(6):1251-1258.
100. Guillygomarc'h A, Mendler MH, Moirand R, et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol. 2001;35(3):344-349.
101. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab. 2009;94(1):103-108.
102. Brand K, Banka CL, Mackman N, et al. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb. 1994;14(5):790-797.
103. Fei H, Berliner JA, Parhami F, Drake TA Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler Thromb. 1993;13(11):1711-1717.
104. Polack B, Pernod G, Barro C, Doussiere J. Role of oxygen radicals in tissue factor induction by endotoxin in blood monocytes. Haemostasis. 1997;27(4):193-200.
105. Sangani RG, Soukup JM, Ghio AJ. Metals in air pollution particles decrease whole-blood coagulation time. Inhal Toxicol. 2010;22(8):621-626.
106. Eto M, Kozai T, Cosentino F, Joch H, Lüscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002; 105(15):1756-1759.
107. Khemasuwan D, Chae YK, Gupta S, et al. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med. 2011;124(9):852-859.
108. Pai M, Evans NS, Shah SJ, et al. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res. 2011;128(5):422-430.
109. Duffy SJ, Biegelsen ES, Holbrook M, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103(23): 2799-2804.
110. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332(8):481-487.
111. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332(8):488-493.
112. Tan KC, Chow WS, Tam SC, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002;87(2):563-568.
113. Ambrosio G, Zweier JL, Jacobus WE, Weisfeldt ML, Flaherty JT. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. Circulation. 1987; 76(4):906-915.
114. Ikeda Y, Young LH, Lefer AM. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reper-fused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol. 2003;41(4):649-656.
115. Say AE, Gursurer M, Yazicioglu MV, Ersek B. Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia. Am Heart J. 2002;143(2):257-264.
116. Oduncu V, Tanalp AC, Erkol A, et al. Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty. Am J Cardiol. 2011; 107(2):179-185.
117. Ndrepepa G, Braun S, Dibra A, et al. Iron status and clinical outcome in patients with coronary artery disease after coronary stenting. Nutr Metab Cardiovasc Dis. 2005;15(6):418-425.
118. Paraskevaidis IA, Iliodromitis EK, Vlahakos D, et al. Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. Eur Heart J. 2005;26(3):263-270.
119. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011;123(15):1622-1632.
120. Kulik A, Ruel M. Lipid-lowering therapy and coronary artery bypass graft surgery: what are the benefits? Curr Opin Cardiol. 2011;26(6):508-517.
121. Muhlestein JB. Cardiac abnormalities in hemochromatosis. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge: Cambridge University Press; 2000:297-311.
122. Zacharski LR, Mckernan L, Metzger ME, et al. Remission of paroxysmal atrial fibrillation with iron reduction in haemophilia A. Haemophilia. 2010;16(5): 726-730.
123. Komatsu T, Tachibana H, Sato Y, et al. Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation. Int Heart J. 2011;52 (6):359-365.
124. Peña JM, Macfadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J. 2011;33(4):531-537.
125. Soaly E, Al Suwaidi J. Statin therapy in heart failure. Expert Rev Cardiovasc Ther. 2005;3(1):5-7.
126. Barton JC, Acton RT, Dawkins FW, et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in Whites and Blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test. 2005;9(3):231-241.
127. Sullivan JL. Iron and sex difference in heart disease risk. Lancet. 1981;1(8233):1293-1294.
128. Jian J, Pelle E, Huang X. Iron and menopause: does increased iron affect the health of postmenopausal women? AntioxidRedox Signal 2009;11(12):2939-2943.
129. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion. 2002;42(9):1135-1139.
130. Salonen JT, Tuomainen TP, Salonen R, Lakka TA Nyyssönen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol. 1998;148(5):445-451.
131. Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? Lancet. 2007;369(9557):168-169.
132. Lieb M, Palm U, Hock B, et al. Effects of alcohol consumption on iron metabolism. Am J Drug Alcohol Abuse. 2011;37(1):68-73.
133. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999; 22(12):1978-1983.
134. Piperno A, Trombini P, Gelosa M, et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens. 2002;20(8):1513-1518.
135. Iwasaki T, Nakajima A, Yoneda M, et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care. 2005;28(10):2486-2491.
136. Casanova-Esteban P, Guiral N, Andrés E, et al. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis. Metabolism. 2011;60(6): 830-834.
137. Montonen J, Boeing H, Steffen A, et al. Body iron stores and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetologia. 2012; 55(10):2613-2621.
138. Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst. 2008; 100(14):996-1002.
139. Fleming DJ, Tucker KL, Jacques PF, et al. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr. 2002;76(6):1375-1384.
140. Beard J. Dietary iron intakes and elevated iron stores in the elderly: is it time to abandon the set-point hypothesis of regulation of iron absorption? Am J Clin Nutr. 2002;76(6):1189-1190.
141. Ellervik C, Tybjærg-Hansen A, Nordestgaard BG. Total mortality by transferrin saturation levels: two general population studies and a metaanalysis. Clin Chem. 2011;57(3):459-466.
142. Mursu J, Robien K, Harnack LJ, Park K, Jacobs DR Jr. Dietary supplements and mortality rate in older women: the Iowa Women's Health Study. Arch Intern Med. 2011;171(18):1625-1633.
143. Cook CI, Yu BP. Iron accumulation in aging: modulation by dietary restriction. Mech Ageing Dev. 1998;102(1):1-13.
144. de Lorgeril M, Salen P. Dietary prevention of coronary heart disease: the Lyon Diet Heart Study and after. World Rev Nutr Diet. 2005;95:103-114.
145. Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci. 2002;967:342-351.
146. Fung TT, Rexrode KM, Mantzoros CS, et al. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation. 2009;119(8):1093-1100
147. Erratum in: Circulation. 2009;119(12):e379.
148. Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep. 1998;47(RR-3):1-29.
149. US Food and Drug Administration. Identification of Iron Used to Fortify Food and in Vitamin and Mineral Supplements as GRAS. Available at: http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?filter= iron&sortColumn=&rpt=scogsListing. Accessed November 20, 2012.
150. Sullivan JL. Misconceptions in the debate on the iron hypothesis. J Nutr Biochem. 2001;12(1):33-37.